RxDoctor Payments Data

Forrest Murphy, MD

Ophthalmology · Redlands, CANPI 1265444541

Payments from drug & device makers

$5,783in general payments, 2019–2025

Across 148 payments — averaging $39.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$2K
  • ANI Pharmaceuticals, Inc.$1K
  • Alcon$725
  • NEW World Medical,inc.$698
  • Amgen$252
  • Johnson & Johnson Surgical Vision, Inc.$151
  • plus $732 from 11 others

What the payments were for

  • Food & beverage$5,68298%
  • Education$1012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,783 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$21,849
Medicare patients
77
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin32$2,796,644
RestasisCyclosporine79$55,032
Prednisolone Acetate849$27,311
RhopressaNetarsudil Mesylate69$23,038
Cyclosporine65$21,841
MoxifloxacinMoxifloxacin Hcl632$13,181
RocklatanNetarsudil Mesylat/Latanoprost34$11,266
Ketorolac Tromethamine669$10,599
Alphagan PBrimonidine Tartrate23$10,535
Brimonidine Tartrate318$8,713
Latanoprost708$8,448
LumiganBimatoprost15$8,416
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat314$4,866
SimbrinzaBrinzolamide/Brimonidine Tart11$2,087
Timolol Maleate173$1,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$2,218$2,796,64432 claims
AbbVieRestasis, Alphagan P, Lumigan$67$73,983117 claims
AlconSimbrinza$725$2,08711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →